Jan 22, 2025 · With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of …

Jan 23, 2025 · Johnson & Johnson (NYSE:JNJ) reported robust operational sales growth of 7% for the full year 2024, excluding the COVID-19 vaccine. The company achieved strong growth …

Johnson & Johnson and its subsidiaries (the Company) have approximately 131,900 employees worldwide engaged in the research and development, manufacture and sale of a broad range …

Jan 22, 2025 · With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of …

Jan 22, 2025 · Johnson& Johnson today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson& Johnson, marked by strong growth, an …

Jan 23, 2025 · Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:00 a.m., Eastern Time. A simultaneous webcast of the call for …

Since January 2024, we invested approximately $50 billion in research and development and other inorganic growth opportunities, including the recently announced planned acquisition of …

Jan 23, 2025 · Johnson & Johnson's 2024 financial report reveals a 4.3% revenue increase, with Daratumumab (Darzalex) reaching $11.67B and Carvykti seeing a 92.7% growth. Key …

Feb 13, 2025 · Dive into Johnson & Johnson's 2024 financial analysis, revealing sales growth, litigation risks, and strategic insights. Key recommendations suggest a cautious hold for …

Jan 22, 2025 · With operational growth of 5.9% except for COVID-19 vaccination contributions, full-year 2024 revenues increased 4.3% to $88.8 billion.